A drug and diagnostic discovery company, ExonHit Therapeutics S.A. (EPA: ALEHT), has extended its strategic collaboration with Allergan, Inc. (NYSE: AGN) for the identification, development and commercialization of drugs targeted at the treatment of neurodegenerative diseases, pain and ophthalmology based on the positive pre-clinical trial results achieved to date.
Exonhit and Allergan have extended their collaboration twice since 2003. The following are the highlights of the current extension:
Upon signing the new agreement, ExonHit also received a payment.
Find more details from the press release.
Comment Preview